Yüklüyor......

Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer

Oncogenic BRAF(V600E) mutations activate MAP kinase signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer (CRC). In BRAF(V600E) mutant CRCs, treatment failure may be related to BRAF(V600E) -mediated apoptosis resistance that occurs by an as yet...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer Ther
Asıl Yazarlar: Kawakami, Hisato, Huang, Shengbing, Pal, Krishnendu, Dutta, Shamit K., Mukhopadhyay, Debabrata, Sinicrope, Frank A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5136313/
https://ncbi.nlm.nih.gov/pubmed/27765849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0017
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!